<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199689</url>
  </required_header>
  <id_info>
    <org_study_id>V503-049</org_study_id>
    <secondary_id>2019-003236-23</secondary_id>
    <secondary_id>V503-049</secondary_id>
    <secondary_id>205346</secondary_id>
    <nct_id>NCT04199689</nct_id>
  </id_info>
  <brief_title>Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)</brief_title>
  <official_title>A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the Prevention of Oral Persistent Infection With HPV Types 16, 18, 31, 33, 45, 52, or 58 in Adult Males, 20 to 45 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the
      9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45 years of age. The primary
      hypothesis tested in this study is that administration of a 3-dose regimen of 9vHPV vaccine
      will reduce the incidence of HPV 16/18/31/33/45/52/58-related oral persistent infection (6
      months or longer) compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Human Papillomavirus (HPV)16/18/31/33/45/52/58-related 6-month Persistent Oral Infection</measure>
    <time_frame>Up to Month 42</time_frame>
    <description>A 6-month persistent infection is defined to have occurred if a participant, after completion of the Month 7 visit, is positive for the same human papillomavirus (HPV) type by the HPV polymerase chain reaction (PCR) assay to at least 1 common gene in Oral Rinse and Gargle (ORG) samples obtained at 2 or more consecutive visits at 6 months (+/-1 month visit window) apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Human Papillomavirus (HPV) 6/11-related 6-month Persistent Oral Infection</measure>
    <time_frame>Up to Month 42</time_frame>
    <description>A 6-month persistent infection is defined to have occurred if a participant, after completion of the Month 7 visit, is positive for the same human papillomavirus (HPV) type by the HPV polymerase chain reaction (PCR) assay to at least 1 common gene in Oral Rinse and Gargle (ORG) samples obtained at 2 or more consecutive visits at 6 months (+/-1 month visit window) apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 Antibodies</measure>
    <time_frame>1 month postdose 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types are measured with competitive Luminex immunoassay (cLIA). Geometric mean titers of antibodies to HPV types will be calculated by exponentiating the mean estimates of natural logarithm of the anti-HPV titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Seroconvert to Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</measure>
    <time_frame>1 month postdose 3 (Month 7)</time_frame>
    <description>Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive by 4 weeks postdose 3. A participant with anti-HPV competitive Luminex immunoassay (cLIA) titer at or above the serostatus cutoff of the cLIA for a given HPV type is considered seropositive for that HPV type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with at Least 1 Solicited Injection-site Adverse Event (AE)</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Solicited injection-site AEs such as redness/erythema, swelling, and tenderness/pain at the injection site will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Elevated Temperature (Fever)</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>Participants are asked to record oral body temperatures. The percentage of participants with elevated temperature (≥37.8°C or 100.0°F) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Report at Least 1 Systemic Adverse Event</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Experience at Least 1 Serious Vaccine-Related Adverse Event</measure>
    <time_frame>Up to Month 42</time_frame>
    <description>A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is another important medical event deemed such by medical or scientific judgment. An SAE that is considered by an investigator (a qualified physician) to be vaccine-related will be reported during entire study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Papillomavirus Infections</condition>
  <arm_group>
    <arm_group_label>9vHPV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9vHPV Vaccine</intervention_name>
    <description>9-valent human papillomavirus vaccine (9vHPV) is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.</description>
    <arm_group_label>9vHPV vaccine</arm_group_label>
    <other_name>GARDASIL®9</other_name>
    <other_name>V503</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Saline for Injection)</intervention_name>
    <description>0.9% sodium chloride given as a 0.5-mL intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has provided written informed consent for the study. The participant may also provide
             consent for future biomedical research. However, the participant may participate in
             the main study without participating in future biomedical research.

          -  Agrees to provide study personnel with a primary telephone number as well as an
             alternate means of contact, if available (such as an alternate telephone number or
             email) for follow-up purposes

          -  Can read, understand, and complete the electronic vaccination report card (eVRC)

          -  Has had at least 1 lifetime sexual partner

        Exclusion Criteria:

          -  Has a history of human papillomavirus (HPV)-related anal lesion (anal intraepithelial
             neoplasia or anal cancer) or HPV related head and neck cancer

          -  Has a history of or clinical evidence at the Day 1 external genital examination of
             HPV-related external lesion

          -  Has clinical evidence at the Day 1 external genital examination of gross genital
             lesion suggesting sexually transmitted disease

          -  Has a fever (defined as oral temperature ≥100.0°F or ≥37.8°C)

          -  Has a history of severe allergic reaction (e.g., swelling of the mouth and throat,
             difficulty breathing, hypotension, or shock) that required medical intervention

          -  Is allergic to any vaccine component, including aluminum, yeast, or BENZONASE®

          -  Has known thrombocytopenia or any coagulation disorder that would contraindicate
             intramuscular injections

          -  Is currently immunocompromised or has been diagnosed as having congenital or acquired
             immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus,
             rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or
             other autoimmune condition

          -  Has a history of splenectomy

          -  Is, at the time of signing informed consent, a user of recreational or illicit drugs
             or has had a recent history (within the last year) of drug or alcohol abuse or
             dependence at the discretion of the investigator. Alcohol abusers are defined as those
             who drink despite recurrent social, interpersonal, and/or legal problems because of
             alcohol use.

          -  Has received within 12 months prior to enrollment, is receiving, or plans to receive
             during the study, the following immunosuppressive therapies: radiation therapy,
             cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin,
             leflunomide (ARAVA®), TNF-α antagonists, monoclonal antibody therapies (including
             rituximab [RITUXAN®]), intravenous immunoglobulin (IVIG), anti-lymphocyte sera, or
             other therapy known to interfere with the immune response. Regarding systemic
             corticosteroids, a participant will be excluded if he is currently receiving steroid
             therapy, has recently received such therapy, or has received 2 or more courses of
             high-dose corticosteroids (≥20 mg/day of prednisone [or equivalent] orally or
             parenterally) lasting at least 1 week in duration in the year prior. Participants
             using inhaled, nasal, or topical steroids are considered eligible for the study.

          -  Has received within the 3 months prior to vaccination, is receiving, or plans to
             receive during the study, any immune globulin product (including RhoGAM™) or
             blood-derived product other than IVIG

          -  Has received inactivated or recombinant vaccines within 14 days prior to vaccination
             or receipt of live vaccines within 21 days prior to vaccination

          -  Is concurrently enrolled in other clinical studies of investigational agents

          -  Has previously received a marketed HPV vaccine, or has participated in a clinical
             trial for any HPV vaccine (receiving either active agent or placebo)

          -  Has engaged in sexual activity 48 hours prior to vaccination. Sexual activity is
             defined as: penile penetrative vaginal intercourse with female partner; penile
             penetrative or receptive anal intercourse with male or female partner; or oral sex
             involving any contact between participant's mouth with a female partner's vagina,
             genital or anal area or male partner's penis or genital or anal area. This also
             includes any contact between participant's partner's mouth with participant's penis,
             genital or anal area.

          -  Is unlikely to adhere to the study procedures, keep appointments, or is planning to
             permanently relocate from the area prior to the completion of the study or to leave
             for an extended period when study visits would need to be scheduled.

          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or
             child) who is investigational site or Sponsor staff directly involved with this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male participants between the ages of 20 and 45 years (inclusive)</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Valley Clinical Trials Inc. ( Site 0002)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-280-4220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials, LLC ( Site 0025)</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>909-883-2999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alta California Medical Group ( Site 0031)</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>805-583-0414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research ( Site 0028)</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>619-660-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc ( Site 0042)</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>925-930-7267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida ( Site 0036)</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-445-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates ( Site 0001)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-212-4187</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center ( Site 0017)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>813-745-6055</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University ( Site 0010)</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-721-8944</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solaris Clinical Research, LLC ( Site 0003)</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>208-288-0123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center ( Site 0044)</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>785-368-0742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC ( Site 0034)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-689-6609</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research Inc ( Site 0011)</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-349-1569</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network LLC ( Site 0035)</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <zip>63042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-972-9600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Reseach, LLC ( Site 0021)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-597-9825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Certified Research Associates ( Site 0041)</name>
      <address>
        <city>Cortland</city>
        <state>New York</state>
        <zip>13045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>607-662-4059</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laser Surgery Care ( Site 0018)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-242-6500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc. ( Site 0008)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>585-288-0890</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury ( Site 0009)</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>704-647-9913</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc. ( Site 0037)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-682-0320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians ( Site 0032)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-650-6155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center ( Site 0043)</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-856-3784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group ( Site 0030)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>423-857-2787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston ( Site 0038)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>409-772-5278</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Center For Drug Development ( Site 0013)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-838-2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research LLC ( Site 0027)</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>361-574-7800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>J Lewis Research Inc/Foothill Family Clinic South ( Site 0006)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-554-0158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>J Lewis Research Inc/Jordan River Family Medicine ( Site 0023)</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-554-0158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center, LLC ( Site 0007)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-817-2442</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc. ( Site 0015)</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>757-591-8100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC. ( Site 0004)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-477-3045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Antwerp ( Site 0352)</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerpen</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3232652130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Femicare VZW ( Site 0350)</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams-Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216808100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro de Investigacion Clinica CIC ( Site 0153)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3013399204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0152)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573164375999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Medica CAIMED ( Site 0156)</name>
      <address>
        <city>Chia</city>
        <state>Cundinamarca</state>
        <zip>250001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573158187608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum ambulantni gynekologie a primarni pece ( Site 0401)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420542221661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>G-CENTRUM Olomouc s.r.o. ( Site 0400)</name>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420585234444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MediStar s.r.o. ( Site 0403)</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420222716273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FN Motol ( Site 0402)</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224434355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 0507)</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33299283715</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne - Hopital F. Mitterrand ( Site 0223)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380295753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi ( Site 0504)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467332335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hopital Hotel Dieu ( Site 0510)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33240083372</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin ( Site 0506)</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33158412860</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infektiologikum Frankfurt-Sachsenhausen ( Site 0456)</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4969695972430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin ( Site 0454)</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493020859400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf ( Site 0451)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940741052682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 0602)</name>
      <address>
        <city>Kfar Saba</city>
        <state>HaMerkaz</state>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297472537</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0601)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247776432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maccabi Health Services ( Site 0604)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6150401</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972508803174</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center. Ein Kerem ( Site 0600)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226779374</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 0551)</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390652662520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico di Bari ( Site 0550)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393483809810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Vittorio Emanuele ( Site 0552)</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390953782641</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Roma &quot;La Sapienza&quot; ( Site 0553)</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393338200853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>P-One Clinic, Keikokai Medical Corp. ( Site 1101)</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81426255216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital ( Site 0952)</name>
      <address>
        <city>Ansan-si</city>
        <state>Kyonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82314124271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 0954)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821046533511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital ( Site 0951)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8228295107</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital ( Site 0950)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82226263050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arke Estudios Clinicos S.A. de C.V. ( Site 0203)</name>
      <address>
        <city>Cdmx</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5215543483950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icaro Investigaciones en Medicina S.A. de C.V. ( Site 0200)</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+526144106319</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asociacion Via Libre ( Site 0250)</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5112039900143</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigaciones Medicas en Salud - INMENSA ( Site 0255)</name>
      <address>
        <city>Lima</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51942128602</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigacion Nutricional - Anexo Huascar ( Site 0251)</name>
      <address>
        <city>Lima</city>
        <zip>15423</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5113496023</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0755)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934978849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAP Centelles ( Site 0751)</name>
      <address>
        <city>Centelles</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34938810485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L Hospitalet ( Site 0754)</name>
      <address>
        <city>L Hospitalet De Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08090</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 1002)</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535#3985</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 1000)</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>88622312345666081</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

